1 / 50

Charles L. Hoppel, M.D. Pharmacology and Medicine Case Western Reserve University

Clinical Phenotype of Mitochondrial Disease. Charles L. Hoppel, M.D. Pharmacology and Medicine Case Western Reserve University Center for Mitochondrial Diseases Center for Inherited Disorders of Energy Metabolism 2008 McKim Conference , Duluth, MN September 17,2008.

roden
Télécharger la présentation

Charles L. Hoppel, M.D. Pharmacology and Medicine Case Western Reserve University

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Clinical Phenotype of Mitochondrial Disease Charles L. Hoppel, M.D. Pharmacology and Medicine Case Western Reserve University Center for Mitochondrial Diseases Center for Inherited Disorders of Energy Metabolism 2008 McKim Conference, Duluth, MN September 17,2008

  2. Clinical Phenotype of Mitochondrial Disease • What is a Jedi Knight? • A perspective on the Dark Side of the Force.

  3. Clinical Phenotype of Mitochondrial Disease • Why study Mitochondria • Mitochondrial Oxidative Phosphorylation • Mitochondrial function in Patients • Respirasomes ?? Supercomplexes!! • Respirasomes in Heart Failure • Summary and Conclusions 2008 McKim Conference, Duluth, MN September 17,2008

  4. Star WarsEpisode I What makes a JEDI Knight?How do you become a JEDI Knight? Adapted from G. Lucas, STAR WARS, Episode I (1999)

  5. Chip with a blood sample • Anakin Skywalker • Midi-chlorian test • Count is over twenty thousand • No one has a count that high NOT even Master Yoda! Adapted from G. Lucas,STAR WARS, Episode I (1999)

  6. Midi-chlorians • Microscopic life-forms • reside with cells • Communicate with the FORCE • We are symbiots with the midi-chlorians(living together with material advantage) Adapted from G. Lucas,STAR WARS, Episode I (1999)

  7. Without midi-chlorians • Life cannot exist and • Have no knowledge of the FORCE. • Midi-chlorians • Speak to us • Telling us the will of the FORCE

  8. Clinical Phenotype of Mitochondrial Disease • Why study Mitochondria • Mitochondrial Oxidative Phosphorylation • Mitochondrial function in Patients • Respirasomes ?? Supercomplexes!! • Respirasomes in Heart Failure • Summary and Conclusions 2008 McKim Conference, Duluth, MN September 17,2008

  9. Oxidative Phosphorylation mitochondria ADP substrates 70 µM ADP 70 µM ADP oxygen consumption 2 mM ADP 200 µM DNP time

  10. Localize Sites of Damage to Electron Transport Chain by Use of Selective Substrates TMPD-asc H+ H+ H+ ADP H+ DHQ Cyt. c Coenzyme Q e- Cyt. c1 AT Pase e- e- e- Cyt. a1a3 (Cu) e- Cyt. b ANT e- e- II IV H+ III e- Fumarate ATP ½O2 + 2H+ I H2O ADP Succinate H+ PO42- H+ NAD+ NADH Glutamate H+

  11. Mitochondrial Oxidation Studies

  12. Clinical Phenotype of Mitochondrial Disease • Why study Mitochondria • Mitochondrial Oxidative Phosphorylation • Mitochondrial function in Patients • Respirasomes ?? Supercomplexes!! • Respirasomes in Heart Failure • Summary and Conclusions 2008 McKim Conference, Duluth, MN September 17,2008

  13. Patient 1 • 56 yo man CC: myalgia and fatigue • 2002 1 month after starting Lipitor (statin) • Generalized fatigue, myalgia and minimal weakness stopped Lipitor in early 2003 • Intermittently elevated CK 506 U/L (N=0-232) • Continued symptoms off lipitor 5 years!! • Exercises regularly

  14. Patient 1 • RX: • Niaspan • Tricor • Metformin • Glucotrol • Lisinopril • Total Cholesterol 188 • LDL 119 • HDL 34.4

  15. 1/2O2 I III IV C Q H2O II Patient 1: Oxidative PhosphorylationnA oxygen/min/mg mito prot

  16. Patient 1: Skeletal Muscle Mitochondria ETC nmoles/min/mg mito prot I III IV C Q II

  17. Patient 1: Skeletal Muscle ETC mol/min/g wet wt I III IV C Q II

  18. Patient 1 Summary • ETC Complex I defect • NADH-linked oxidation • Succinate oxidation • Quinol oxidation • Cyto c oxidation • Complex I/III • Complex I

  19. Patient 1 Summary • ETC Complex I defect Statin – Induced? What type of mechanism? Statin – uncovered a primary defect? In a 52 yo man!!!! Statin – Induced coenzyme Q deficiency? Complex I

  20. Patient 2 (Zinn) • 20 yo age 3 yr: bilateral hearing loss age 12 yr: exercise intolerance age 17 yr: cardiomyopathy plasma lactate 4.9 mM L/P ratio 21 1995 biopsy - focalmito 1996 biopsy - normal negative for mDNA analysis

  21. 1/2O2 I III IV C Q H2O II Patient 2: Oxidative PhosphorylationnA oxygen/min/mg mito prot

  22. Patient 2: Skeletal Muscle Mitochondria ETC nmoles/min/mg mito prot I III IV C Q II

  23. Patient 2: Skeletal Muscle ETC mol/min/g wet wt I III IV C Q II

  24. Patient 2 1000 High ADP Respiration 900 800 Pt 2 700 600 Controls 500 nAO/min/mg protein 400 300 200 100 0 2-KG Glutamate Pyruvate Palm-carn Succinate Palm-CoA TMPD/Asc Duroquinol

  25. Patient 2 Summary • ETC Complex III defect • NADH-linked oxidation • Succinate oxidation • Quinol oxidation • Cyto c oxidation • Complex I/III • Complex III

  26. Patient 3 • 3 1/2 yo girl Björnstad syndrome Sensorineural deafness Pili torti Referred for muscle biopsy and isolation of skeletal muscle mitochondria Also studied in Seidman Lab at Harvard

  27. 1/2O2 I III IV C Q H2O II Patient 3: Oxidative PhosphorylationnA oxygen/min/mg mito prot

  28. Patient 3: Skeletal Muscle Mitochondria ETC nmoles/min/mg mito prot I III IV C Q II

  29. Patient 3: Skeletal Muscle ETC mol/min/g wet wt I III IV C Q II

  30. Patient 3 Summary • ETC Complex III defect • NADH-linked oxidation • Succinate oxidation • Quinol oxidation • Cyto c oxidation • Complex I/III and II/III • Complex III

  31. Original ArticleMissense Mutations in the BCS1L Gene as a Cause of the Björnstad Syndrome J. Travis Hinson, B.A., Valeria R. Fantin, Ph.D., Jost Schönberger, M.D., Noralv Breivik, M.D., Geir Siem, M.D., Barbara McDonough, R.N., Pankaj Sharma, M.D., Ph.D., Ivan Keogh, M.D., Ricardo Godinho, M.D., Ph.D., Felipe Santos, M.D., Alfonso Esparza, M.D., Yamileth Nicolau, M.D., Edgar Selvaag, M.D., Ph.D., M.H.A., Bruce H. Cohen, M.D., Charles L. Hoppel, M.D., Lisbeth Tranebjærg, M.D., Ph.D., Roland D. Eavey, M.D., S.M., J.G. Seidman, Ph.D., and Christine E. Seidman, M.D. N Engl J Med Volume 356(8):809-819 February 22, 2007

  32. Conclusion • BCS1L mutations cause disease phenotypes ranging from highly restricted pili torti and sensorineural hearing loss (the Björnstad syndrome) to profound multisystem organ failure (complex III deficiency and the GRACILE syndrome) • All BCS1L mutations disrupted the assembly of mitochondrial respirasomes (the basic unit for respiration in human mitochondria), but the clinical expression of the mutations was correlated with the production of reactive oxygen species • Mutations that cause the Björnstad syndrome illustrate the exquisite sensitivity of ear and hair tissues to mitochondrial function, particularly to the production of reactive oxygen species

  33. Clinical Phenotype of Mitochondrial Disease • Why study Mitochondria • Mitochondrial Oxidative Phosphorylation • Mitochondrial function in Patients • Respirasomes ?? Supercomplexes!! • Respirasomes in Heart Failure • Summary and Conclusions 2008 McKim Conference, Duluth, MN September 17,2008

  34. What is Blue Native Electrophoresis? Native PAGE (no SDS) - acrylamide gradient from 3-4% down to 12-20% Nonionic detergents - stabilize hydrophobic membrane protein complexes Add Coomassie G-250 - makes all such complexes negatively charged Complexes “stick” at gel pore size ~ complex diameter Individual Complexes Triton X-100, 3 mg / mg protein Coomassie G-250 Restain

  35. What is Blue Native Electrophoresis? Native PAGE (no SDS) - acrylamide gradient from 3-4% down to 12-20% Nonionic detergents - stabilize hydrophobic membrane protein complexes Add Coomassie G-250 - makes all such complexes negatively charged Complexes “stick” at gel pore size ~ complex diameter Individual Complexes Triton X-100, 3 mg / mg protein Complex IV COX4 Complex I NDUFB8 Complex III Rieske Coomassie G-250 Restain Complex I (Complex III)2 Complex IV

  36. What is Blue Native Electrophoresis? Native PAGE (no SDS) - acrylamide gradient from 3-4% down to 12-20% Nonionic detergents - stabilize hydrophobic membrane protein complexes Add Coomassie G-250 - makes all such complexes negatively charged Complexes “stick” at gel pore size ~ complex diameter Individual Complexes Triton X-100, 3 mg / mg protein Supercomplexes Digitonin, 6 mg / mg protein Coomassie G-250 Restain Complex I NDUFB8 Coomassie G-250 Restain Complex IV COX4 Complex III Rieske Supercomplexes Complex I (Complex III)2 Complex IV

  37. What is Blue Native Electrophoresis? Native PAGE (no SDS) - acrylamide gradient from 3-4% down to 12-20% Nonionic detergents - stabilize hydrophobic membrane protein complexes Add Coomassie G-250 - makes all such complexes negatively charged Complexes “stick” at gel pore size ~ complex diameter Individual Complexes Triton X-100, 3 mg / mg protein Supercomplexes Digitonin, 6 mg / mg protein Complex III Rieske Complex I NDUFB8 Complex IV COX4 Coomassie G-250 Restain Complex I NDUFB8 Coomassie G-250 Restain Complex IV COX4 Complex III Rieske Supercomplexes Complex I (Complex III)2 Complex IV

  38. What is Blue Native Electrophoresis? Native PAGE (no SDS) - acrylamide gradient from 3-4% down to 12-20% Nonionic detergents - stabilize hydrophobic membrane protein complexes Add Coomassie G-250 - makes all such complexes negatively charged Complexes “stick” at gel pore size ~ complex diameter Individual Complexes Triton X-100, 3 mg / mg protein Supercomplexes Digitonin, 6 mg / mg protein Complex IV Activity Complex I NDUFB8 Coomassie G-250 Restain Complex IV COX4 Complex I NDUFB8 Complex III Rieske Coomassie G-250 Restain Complex IV COX4 Complex III Rieske Supercomplexes Complex I (Complex III)2 Complex IV

  39. O2 CytC IV III III I Q H+ H+ H+ NADH Side view (matrix -> bottom of page) Cartoon with associated factors What are supercomplexes? (Complex I monomer) + (Complex III dimer) –> core S0 supercomplex S0 + 1 to 4 (Complex IV monomer) –> “respirasome” supercomplexes S1 through S4 S1 architecture at ~ 4 Angstrom resolution White = Complex I Red = (Complex III)2 Green = Complex IV Side view Top view Schäfer E, Seelert H et al. (2006) J. Biol. Chem. 281, 15370-5 Schäfer E, Dencher NA et al. (2007) Biochemistry 46, 12579-85.

  40. Clinical Phenotype of Mitochondrial Disease • Why study Mitochondria • Mitochondrial Oxidative Phosphorylation • Mitochondrial function in Patients • Respirasomes ?? Supercomplexes!! • Respirasomes in Heart Failure • Summary and Conclusions 2008 McKim Conference, Duluth, MN September 17,2008

  41. State 3 respiratory rates

  42. Uncoupled (200 µM dinitrophenol) respiration

  43. ETC complexes in isolated heart mitochondria

  44. kDa 1700 1000 750 500 200 130 9 8 7 6 5 4 3 2 1 C I C V C III C IV C II 1D-BN-PAGE control heart failure ETC supercomplexes in heart IFM

  45. SSM IFM C I C V C III C IV C II 1D-BN-PAGE control heart failure control heart failure ETC individual complexes in heart mitochondria

  46. CONCLUSION In HF the mitochondrial defect lies in the supermolecular assembly of the ETC in functional respirasomes. We propose that phosphorylation of specific complex IV subunits is involved in disruption of supercomplex assembly of the mitochondrial ETC in HF.

  47. PPG - Laboratory Mariana Rosca, M.D. Edwin Vazquez, B.S. Janos Kerner, Ph.D. Margaret Chandler, Ph.D. William Parland, Ph.D. David Kehres, Ph.D. Hiral Patel Colin Naples Acknowledgements • Collaborators • Hani Sabbah, Ph.D. • Henry Ford Hospital • Detroit, MI • William Stanley, Ph.D. • University of Maryland • Baltimore, MD • Center for Inherited Disorders of Energy Metabolism Clinical • Bruce Cohen, MD • Sumit Parikh, MD • Douglas Kerr, MD,PhD • Shawn McCandless • EPrint • Cardiovascular Research • August 18, 2008 Funding Support: PPG P01 HL074237 P01 AG015885 R01 HL 64848

More Related